Phase II study of clinical activity and proteomic pathway profiling of the VEGFR2 [vascular endothelial growth factor receptor 2] inhibitor, ZD6474 (vandetanib) in women with relapsed or refractory epithelial ovarian, fallopian tube or primary peritoneal cancer.

Trial Profile

Phase II study of clinical activity and proteomic pathway profiling of the VEGFR2 [vascular endothelial growth factor receptor 2] inhibitor, ZD6474 (vandetanib) in women with relapsed or refractory epithelial ovarian, fallopian tube or primary peritoneal cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Actual end date (1 Oct 2009) added as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top